San Diego

CH4 Global Appoints Strategic Chief Financial Officer to Propel Profitable Growth and Global Expansion

Retrieved on: 
Wednesday, November 8, 2023

HENDERSON, Nev., Nov. 8, 2023 /PRNewswire/ -- CH4 Global, Inc., a climate tech company on an urgent mission to bend the climate curve, today announced the appointment of Steve Chun as Chief Financial Officer (CFO). Mr. Chun will play a pivotal role advancing the company's ambitious growth plans by helping it drive scalable, profitable production of products that enable the food industry value chain to radically reduce GHG emissions.

Key Points: 
  • HENDERSON, Nev., Nov. 8, 2023 /PRNewswire/ -- CH4 Global, Inc., a climate tech company on an urgent mission to bend the climate curve, today announced the appointment of Steve Chun as Chief Financial Officer (CFO).
  • "This strategic appointment stands as a momentous juncture in our journey towards operational profitability and worldwide reach.
  • His illustrious financial stewardship credentials exemplify the exacting strategic acumen we require to expedite and fortify our mission with unwavering determination," remarked Dr. Meller, CEO of CH4 Global.
  • His areas of expertise encompass private equity funding, credit management, structured financial strategies, cost optimization, financial modeling, and supply chain refinement.

CancerVAX CEO Ryan Davies Discusses Cancer Drug Development with Dr. Ezra Cohen

Retrieved on: 
Thursday, November 2, 2023

LEHI, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago.

Key Points: 
  • LEHI, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago.
  • “I got into medicine to make a difference in people’s lives, said Dr. Cohen.
  • “I realized that cancer patients needed more focus and more attention than other patient groups.
  • Cohen is a lovely man with incredible experience and noble intentions,” said CancerVax CEO, Ryan Davies.

What Will Happen to the U.S. and Global Economy in the Next 50 Years?

Retrieved on: 
Thursday, October 19, 2023

SAN DIEGO, Oct. 19, 2023 /PRNewswire/ -- With so much talk of doom and gloom in the U.S. and abroad, it is easy to worry that life will only get worse in the next half century. But according to Alan Nevin, a demographer, economist and author of the new book, The Next Half Century, the data show something much brighter. Global changes in population, lifestyle, education and employment point to the U.S. continuing to lead the way in creating new industries and jobs.

Key Points: 
  • But according to Alan Nevin, a demographer, economist and author of the new book, The Next Half Century , the data show something much brighter.
  • Global changes in population, lifestyle, education and employment point to the U.S. continuing to lead the way in creating new industries and jobs.
  • Nevin has devoted his career to studying the growth of the world's leading economies, with a focus on real estate development and trends.
  • An essential read for the thoughtful person who wants to understand where we are headed and what to expect."

Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1

Retrieved on: 
Monday, October 16, 2023

MIAMI, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Helocyte, Inc. (“Helocyte”), a subsidiary company of Fortress Biotech, Inc. (“Fortress”) (Nasdaq: FBIO), today announced that it executed an exclusive option agreement with City of Hope for patent rights to use Triplex, a cytomegalovirus vaccine, in combination with cytomegalovirus (“CMV”)-specific, Anti-Human Immunodeficiency Virus (“HIV”) Chimeric Antigen Receptor (“CAR”) (collectively, CMV/HIV-CAR) T Cells for the treatment of adults living with HIV. Triplex was initially developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Helocyte in 2015.

Key Points: 
  • Triplex was initially developed by City of Hope , one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Helocyte in 2015.
  • Additionally, the California Institute for Regenerative Medicine (“CIRM”) recently awarded a $11.3 million grant to City of Hope to fund a Phase 1 clinical trial.
  • The trial will initially enroll at City of Hope and University of California at San Diego.
  • The study illustrated the potential long-term durability of the combination therapy, which induced therapeutic immune cells to take hold in bone marrow.

Pulmonary Fibrosis Foundation Expands Care Center Network for PF Patients

Retrieved on: 
Thursday, October 12, 2023

CHICAGO, Oct. 12, 2023 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) announced that seven medical centers have joined the PFF Care Center Network (CCN) as Clinical Associate members, a new membership option. Each of these Clinical Associates will collaborate with an existing Care Center Network site to help bring the resources of the PFF to even more people living with pulmonary fibrosis (PF) and interstitial lung disease (ILD). The Care Center Network includes 81 CCN sites and seven Clinical Associates in 39 states.

Key Points: 
  • CHICAGO, Oct. 12, 2023 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) announced that seven medical centers have joined the PFF Care Center Network (CCN) as Clinical Associate members, a new membership option.
  • Each of these Clinical Associates will collaborate with an existing Care Center Network site to help bring the resources of the PFF to even more people living with pulmonary fibrosis (PF) and interstitial lung disease (ILD).
  • The newly designated Clinical Associate members of the PFF Care Center Network are:
    Chest Medicine Associates Center for Interstitial Lung Disease (South Portland, ME): Dr. Meagan Moore, Center Director
    Ochsner LSU Health Shreveport – Academic Medical Center (Shreveport, LA): Dr. Prangthip Charoenpong, Center Director
    University of New Mexico (Albuquerque, NM): Dr. Nour Ass'ad, Center Director
    Through the CCN, Care Centers and Clinical Associates collaborate to promote and provide quality care to those living with PF.
  • Each Clinical Associate is paired with a current Care Center member so they may collaborate to expand and improve pulmonary fibrosis care.

BLITMAP: WORLD'S FIRST COMIC BOOK WHERE EVERY COVER IS A VARIANT COVER

Retrieved on: 
Friday, October 6, 2023

NEW YORK, Oct. 6, 2023 /PRNewswire/ -- Sup Inc., a team comprised of former video game devs, artists, and the creator of Vine today confirmed the release date of BLITMAP #1, a thrilling new sci-fi series set in a vibrant solarpunk metropolis. In partnership with Titan Comics, the first issue in this 6-issue series arrives at comic book stores worldwide on October 25th. However, attendees of New York Comic-Con will be able to pick up a copy two weeks early directly from the Sup Inc. booth.

Key Points: 
  • In partnership with Titan Comics, the first issue in this 6-issue series arrives at comic book stores worldwide on October 25th.
  • However, attendees of New York Comic-Con will be able to pick up a copy two weeks early directly from the Sup Inc. booth.
  • No one in the world will have the same cover as you.
  • Find out more information on our YouTube Channel: @sup.worlds
    Check out our YouTube channel for more videos like this: Every Cover is Unique

Concentric by Ginkgo to Support CDC-Funded Consortium to Develop New AI-Based Technologies for Epidemic Forecasting

Retrieved on: 
Thursday, October 5, 2023

BOSTON, Oct. 5, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its biosecurity and public health unit, Concentric by Ginkgo, will partner with Northeastern University, which has received a grant from the Centers of Disease Control and Prevention over the next five years to head an innovation center led by a consortium of organizations designed to help the United States to detect and prepare for the next outbreak of infectious disease.

Key Points: 
  • With the CDC's support, Northeastern will lead a nationwide consortium to develop systems to prepare local communities and hospitals across various geographic regions—including rural areas—for outbreaks, according to the university's announcement .
  • Concentric will contribute its unique blend of computational epidemiology, risk modeling, and social science expertise, supported by an extensive laboratory network.
  • Concentric will also support development of new AI-based early warning systems capable of synthesizing multiple indicators to anticipate sharp changes of disease activity.
  • "We are thrilled to partner with CDC, Northeastern University, and the EPISTORM consortium to develop new technologies for early warning and epidemic forecasting," said Nita Madhav, Head of Epidemiology and Global Risk Analytics at Concentric by Ginkgo.

AmbioPharm Appoints Industry Veteran Brian Gregg as CEO

Retrieved on: 
Monday, October 2, 2023

AmbioPharm, a worldwide leader in peptide active pharmaceutical ingredient (API) contract development and manufacturing organization (CDMO) services, announced the appointment of industry veteran Brian Gregg as Chief Executive Officer, today.

Key Points: 
  • AmbioPharm, a worldwide leader in peptide active pharmaceutical ingredient (API) contract development and manufacturing organization (CDMO) services, announced the appointment of industry veteran Brian Gregg as Chief Executive Officer, today.
  • Mr. Gregg, who has more than 30 years of experience in the peptide CDMO industry, succeeds Tim Nieters, who will be stepping down after 7 years with the company.
  • Mr. Gregg will play a pivotal role in expanding AmbioPharm’s leadership role in the fast-growing peptide CDMO market and growing the company’s global customer base.
  • Dr. Juncai (Chris) Bai, Chairman of the Company, said, “We are excited to welcome Brian to our executive team.

San Diego State University’s Snapdragon Stadium Gets a Cellular Upgrade with MatSing Lens Antennas

Retrieved on: 
Wednesday, September 13, 2023

MatSing , the pioneer and innovator of high-capacity lens antennas, today announced an upgrade of the existing mobile network at Snapdragon Stadium located in the San Diego State University (SDSU) main campus in Mission Valley.

Key Points: 
  • MatSing , the pioneer and innovator of high-capacity lens antennas, today announced an upgrade of the existing mobile network at Snapdragon Stadium located in the San Diego State University (SDSU) main campus in Mission Valley.
  • The 35,000 capacity stadium, home to several teams including SDSU Aztecs, San Diego Wave FC of the National Women’s Soccer League (NWSL), and San Diego Legion of the Major League Rugby (MLR), also hosts a packed year-round schedule of music events and performances.
  • Bo Larsson, MatSing’s CEO, stated, “Our involvement at Snapdragon Stadium began last year when our multibeam lens antennas were deployed to deliver high-capacity mid-band connectivity in the field area.
  • Being a brand-new stadium, with many sporting and music events on the calendar, the need arose this summer to expand connectivity to the outdoors.

Former NFL Greats "Pass the Pigskin" with Leading Pork Rind Brand Throughout 15th Annual Pork Rind Appreciation Day® Campaign

Retrieved on: 
Tuesday, September 5, 2023

DALLAS, Sept. 5, 2023 /PRNewswire/ -- Southern Recipe Small Batch pork rinds has announced its fifteenth annual Pork Rind Appreciation Day® campaign. The beloved foodie holiday, which has gained national recognition as being tied to its founding brands, will again support Coach Ditka's Gridiron Greats Assistance Fund (GGAF). Pork rind fans and snack lovers alike are encouraged to "Pass the Pigskin" with Southern Recipe Small Batch, leading up to the biggest football day of the year on February 11th, as Southern Recipe Small Batch brings awareness and funding to one of the game's most important charities. By playing along, consumers will have a chance to win $5,000, unprecedented branded swag and of course, free pork rinds. 

Key Points: 
  • DALLAS, Sept. 5, 2023 /PRNewswire/ -- Southern Recipe Small Batch pork rinds has announced its fifteenth annual Pork Rind Appreciation Day® campaign.
  • By playing along, consumers will have a chance to win $5,000, unprecedented branded swag and of course, free pork rinds.
  • In our 15th year of initiating Pork Rind Appreciation Day, we also celebrate this special charity and the pork rind category simultaneously.
  • In an extraordinary effort each year, Southern Recipe Small Batch works to raise unprecedented awareness through a holiday America can get behind: Pork Rind Appreciation Day.